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Platelet function is influenced by the platelet thiol-
disulfide balance. Platelet activation resulted in 440%
increase in surface protein thiol groups. Two proteins
that presented free thiol(s) on the activated platelet sur-
face were protein-disulfide isomerase (PDI) and glyco-
protein 1ba (GP1ba). PDI contains two active site dithi-
ols/disulfides. The active sites of 26% of the PDI on
resting platelets was in the dithiol form, compared with
81% in the dithiol form on activated platelets. Similarly,
GP1ba presented one or more free thiols on the acti-
vated platelet surface but not on resting platelets. Anti-
PDI antibodies increased the dissociation constant for
binding of vWF to platelets by ;50% and PDI and GP1ba
were sufficiently close on the platelet surface to allow
fluorescence resonance energy transfer between chro-
mophores attached to PDI and GP1ba. Incubation of
resting platelets with anti-PDI antibodies followed by
activation with thrombin enhanced labeling and bind-
ing of monoclonal antibodies to the N-terminal region of
GP1ba on the activated platelet surface. These observa-
tions indicated that platelet activation triggered reduc-
tion of the active site disulfides of PDI and a conforma-
tional change in GP1ba that resulted in exposure of a
free thiol(s).
The platelet thiol-disulfide balance is important for platelet
function. Perturbation of platelet thiol status effects platelet
aggregation and release. The low Mr thiol compounds, reduced
glutathione (GSH), cysteine, and 6-mercaptopurine, inhibit
platelet aggregation induced by several agonists, while the
disulfide-bond reducing agents dithiothreitol and b-mercapto-
ethanol promote aggregation (1). In addition, reaction of plate-
let sulfhydryl groups with the thiol specific compounds, dia-
mide and N-ethylmaleimide, inhibits in vitro aggregation and
clot retraction (2–5). These results imply that certain platelet
thiol groups are critical for platelet aggregation. Furthermore,
the observation that specific depletion of platelet GSH by
1-chloro-2,4-dinitrobenzene only marginally effects platelet ag-
gregability implies that the critical thiol groups are associated
with protein (6). In support of this notion, Yamada et al. (7)
have shown that the anti-platelet aggregation actions of 2,29-
dithiobis(N-2-hydroxypropylbenzamide) are mediated through
interaction of the compound with platelet protein thiol groups.
Protein-disulfide isomerase (PDI)1 is a noncovalent ho-
modimer with a subunit molecular mass of 57 kDa that cata-
lyzes thiol-disulfide interchanges that can result in formation,
reduction, or rearrangement of protein disulfide bonds. It is
generally considered that PDI is important for proper folding
and disulfide bonding of nascent proteins in the endoplasmic
reticulum (8–10). PDI also functions as the b subunits of
prolyl-4-hyroxylase (11, 12) and the b subunit of triglyceride
transfer protein complex (13, 14). Bovine aortic endothelial
cells (15), rat hepatocytes (16), rat pancreatic cells (17), and
human B cells (18, 19) secrete PDI which associates with the
cell surface, and murine fibroblasts secrete PDI in response to
treatment with calcium ionophore (20). Cell surface PDI has
been implicated in reduction of the disulfide-linked diptheria
toxin heterodimer (21, 22), cell surface events which trigger
entry of the human immunodeficiency virus into lymphoid cells
(23), shedding of the human thyrotropin receptor ectodomain
(24), and as a cell surface recognition/adhesion molecule during
neuronal differentiation of the retina (25). PDI is also on the
external surface of the platelet plasma membrane and can
catalyze rearrangement of disulfide bonds in scrambled ribo-
nuclease (26, 27).
Increase or decrease in PDI on the surface of HT1080 human
fibrosarcoma cells is associated with increase or decrease in cell
surface protein thiols (28) and cell surface PDI has been impli-
cated in the increase in surface protein thiol content of human
lymphocytes following mitogen activation (19, 29). These obser-
vations indicated that secreted PDI can control the redox state
of existing exofacial protein thiols or reactive disulfide bonds.
We have examined the redox properties of PDI on the platelet
plasma membrane.
Platelet activation and aggregation resulted in 440% in-
crease in surface protein thiol groups. Both PDI and the von
Willebrand factor receptor, glycoprotein 1ba (GP1ba), ex-
pressed free thiols on the activated platelet surface. Moreover,
PDI and GP1ba were in close proximity on the activated plate-
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let surface. These findings demonstrated that platelet activa-
tion/aggregation triggered reduction of the active site disulfides
of PDI and a conformational change in GP1ba that resulted in
exposure of a free thiol(s). The close proximity of PDI and
GP1ba on the activated platelet surface suggested that PDI
may have participated in the conformational change in GP1ba.
EXPERIMENTAL PROCEDURES
Reagents and Chemicals—HEPES, apyrase (grade VII), leupeptin,
phenylmethylsulfonyl fluoride, streptavidin-agarose, iodoacetamide,
GSH, and dithiothreitol were purchased from Sigma, and Trasylol
(aprotinin) from Bayer Australia, Sydney, New South Wales, Australia.
D-Phe-Pro-Arg-chloromethyl ketone was obtained from Calbiochem,
San Diego, CA. 3-(N-Maleimidylpropionyl)biocytin (MPB) was pur-
chased from Molecular Probes, Eugene, OR, and sulfosuccinimidobiotin
(SSB) from Pierce. PolyScreen polyvinyldiethylene fluoride (PVDF)
transfer membrane, Western blot chemiluminescence reagent, and re-
flection autoradiography film were purchased from DuPont, Boston,
MA. All other chemicals were of reagent grade.
Proteins—PDI was purified from human placenta according to the
method of Lambert and Freedman (30) with modifications described by
Hotchkiss et al. (31). Human a-thrombin was prepared as described
previously (32), and the active enzyme concentration determined by
active site titration (33). Rabbit polyclonal antibodies were developed
against purified human placenta PDI in New Zealand White rabbits
and affinity purified on a PDI-Affi-Gel 15 matrix (Bio-Rad). Streptavi-
din-horseradish peroxidase (HRP) was from Amersham Australia, Syd-
ney, NSW, and swine anti-rabbit IgG HRP conjugated antibodies were
from Dako Corporation, Carpinteria, CA. All proteins were aliquoted
and stored at 280 °C until use.
Platelet Preparation—Platelets were isolated from whole blood as
described previously (34), with the following modifications. The plate-
lets were washed and incubated at 37 °C for 15 min in Ca21- and bovine
serum albumin (BSA)-free Tyrode buffer containing 2 units/ml apyrase
to minimize platelet activation. Following two further washes in
apyrase-free Tyrode buffer the platelets were resuspended in 20 mM
HEPES, 137 mM NaCl, 4 mM KCl, 0.5 mM Na2HPO4, 0.1 mM CaCl2, pH
7.4, buffer. Activation of platelets was with 30 nM human a-thrombin
for 2 min at 37 °C on a rotating wheel. Thrombin and platelet enzymes
were quenched with 5 mM D-Phe-Pro-Arg-chloromethyl ketone and 10
mM leupeptin. Platelet releasate was separated from activated platelets
by centrifugation at 2,000 3 g for 20 min at 4 °C. The total protein in
releasate from 1 3 109 activated platelets per ml was 0.14 mg/ml using
the BCA protein assay (Pierce). Platelet lysates were prepared by
washing platelets twice with phosphate-buffered saline (PBS) by cen-
trifugation at 2,000 3 g for 20 min at 4 °C, resuspension in 50 mM
Tris-HCl, 0.5 M NaCl, pH 8.0, buffer containing 1% Triton X-100, 10 mM
leupeptin, 10 mM aprotinin, 2 mM phenylmethylsulfonyl fluoride, and 5
mM EDTA, and sonication at 4 °C. The total protein in 1 3 109 sonicated
platelets per ml was 1.0 mg/ml using the BCA protein assay (Pierce).
Labeling of Platelets with SSB or MPB—Labeling with SSB was a
modification of the method of Ingalls et al. (35), while labeling with
MPB was a modification of the method of Roffman et al. (36). Resting or
activated platelets (1 ml of ;7 3 108 per ml for SSB and ;0.4–2 3 109
per ml for MPB) were incubated with SSB (1 mM) or MPB (100 mM) for
30 min at room temperature on a rotating wheel. On some occasions,
resting platelets (1 ml of 1.3 3 109 per ml) were incubated with 50 mM
dithiothreitol for 30 min at room temperature prior to labeling with
MPB. On another occasion, resting platelets (1 ml of 0.4 3 109 per ml)
were incubated with 20 mg/ml ReoPro (Centocor B.V., Leiden, The
Netherlands) and 5 mM EDTA for 30 min at room temperature, prior to
activation with thrombin and labeling with MPB. Unreacted SSB was
quenched with glycine (2 mM), and unreacted MPB with GSH (200 mM),
for 30 min at room temperature. The unreacted GSH was quenched
with iodoacetamide (400 mM) for 10 min at room temperature. The
labeled platelets were washed twice with PBS and sonicated as de-
scribed above. An aliquot of labeled platelet sonicate was set aside for
Western blotting with streptavidin-HRP. Streptavidin-agarose beads
(100 ml of packed beads for SSB or 25 ml of packed beads for MPB) were
incubated with the platelet sonicates for 1 h at 4 °C on a rotating wheel
to isolate the biotin-labeled proteins. The streptavidin-agarose beads
were washed 5 times with 50 mM Tris-HCl, 0.15 M NaCl, 0.05% Triton
X-100, pH 8.0, buffer. The beads were suspended in 200 ml (SSB) or 50
ml (MPB) of SDS-Laemmli buffer and boiled for 2 min.
MPB was also used to label purified human placenta PDI. PDI (0.5
mM), or PDI preincubated with dithiothreitol (5 mM) for 30 min, was
labeled with MPB (100 mM) for 30 min. Unreacted MPB was quenched
with GSH (200 mM) for 10 min and iodoacetamide (400 mM) added for 10
min to quench unreacted GSH. All incubations were performed at room
temperature in 20 mM HEPES, 0.14 M NaCl, pH 7.4, buffer.
Immunoprecipitation of Platelet Surface Glycoproteins—Resting or
activated platelets were labeled with either SSB or MPB as described
above and resuspended in PBS containing 1% BSA. The labeled plate-
lets were incubated for 30 min at 4 °C on a rotating wheel with 10 mg/ml
of either control murine monoclonal antibody (MOPC21) or murine
monoclonal antibodies that recognize either GP1ba (AK3) or aIIbb3
(AP2). The platelets were washed three times with PBS, lysed in 10 mM
Tris-HCl, 0.15 M NaCl, pH 8.0, buffer containing 0.5% Triton X-100,
0.05% Tween 20, 10 mM leupeptin, 10 mM aprotinin, 2 mM phenylmeth-
ylsulfonyl fluoride, and 5 mM EDTA, sonicated as described above,
clarified by centrifugation at 12,000 3 g for 30 min at 4 °C, and incu-
bated with sheep anti-mouse coated Dynabeads (Dynal, Victoria, Aus-
tralia) for 2 h at 4 °C on a rotating wheel. The Dynabeads were washed
five times with PBS, resuspended in SDS-Laemmli buffer, and boiled
for 2 min.
SDS-PAGE and Western Blotting—Samples were resolved on 10,
12, or 5–15% SDS-PAGE under nonreducing conditions according to
Laemmli (37), transferred to PVDF membrane, developed according to
the manufacturers instructions (DuPont), and visualized using chemi-
luminescence. Affinity-purified rabbit anti-PDI polyclonal antibodies
were used at a final dilution of 1:5000, swine anti-rabbit HRP-conju-
gated antibodies at 1:1000 dilution, and streptavidin-HRP at 1:2000
dilution.
Quantitation of SSB- and MPB-labeled Platelet Surface Proteins—
SSB- or MPB-labeled platelet surface proteins were quantitated by
densitometry using a Model GS-300 Hoeffer Scientific Instruments
scanning densitometer. SSB- or MPB-labeled PDI was quantitated by
relating band intensity to a standard curve constructed using purified
placenta PDI. Total protein estimations (BCA Protein Assay, Pierce,
Rockford, IL) were performed on all platelet samples prior to SSB or
MPB labeling and after platelet sonication to correct for platelet loss
during the labeling and washing procedures. This loss was always
,20%.
Quantitation of Platelet Low Mr Thiol Compounds—Platelet releas-
ate was separated from 1.5 3 109 thrombin-activated platelets in 1 ml
by centrifugation at 2,000 3 g for 20 min at 4 °C. The total protein in
releasate and platelet sonicate was 0.21 and 1.5 mg/ml, respectively,
using the BCA protein assay (Pierce, Rockford, IL). The platelet low Mr
thiol compounds were derivatized with the fluorescent compound,
7-benzo-2-oxa-1,3-diazole-4-sulfonic acid, and resolved by reverse-
phase HPLC as described previously (38). The starting sample was
diluted 9.45-fold during derivatization and 20 ml was injected onto
HPLC.
Flow Cytometry—Flow cytometry was performed using a FACStar
Plus cytometer (Becton Dickinson, San Jose, CA) with argon ion laser
exitation at 488 nm. Emission spectra were collected using a 530 6 30
nm band pass filter for fluorescein isothiocyanate and Alexa-488, or a
585 6 45 nm band pass filter for phycoerythrin (PE). Ten thousand
platelets were acquired at a flow rate of 500–1000 particles per second.
Binding of vWF to Platelets—Purified human plasma vWF was a gift
from Dr. M. Berndt (39). The vWF was labeled with the fluorochrome,
Alexa-488, according to the manufacturer’s instructions (Molecular
Probes, Eugene, OR). Briefly, vWF was mixed with Alexa-488 at pH 8.3
with constant stirring at room temperature for 60 min. The reaction
was quenched with hydroxylamine and the unconjugated dye removed
by dialysis against PBS. The concentration of the vWf-Alexa conjugate
was determined by protein assay (BCA Protein Assay, Pierce). vWF and
Alexa-488-labeled vWF were resolved on 1% agarose gel electrophoresis
according to Ruggeri and Zimmerman (40). There was no apparent
difference in the multimer distribution of unlabeled versus Alexa-488-
labeled vWF.
Washed platelets were prepared as described above and resuspended
at 2 3 106 platelets/ml in PBS containing 1% BSA and 10 mM EDTA.
Platelets were incubated with 20 mg/ml of the anti-platelet FcgRIIA
receptor monoclonal antibody, IV.3, for 10 min at room temperature and
then with 0 to 200 mg/ml of either preimmune rabbit IgG or anti-PDI
IgG for a further 30 min at room temperature. The blocked platelets
were incubated with 0.1 to 10 mg/ml vWF-Alexa and 1 mg/ml ristocetin
(Sigma) for 10 min at room temperature. Unbound vWF-Alexa was
removed by washing the platelets three times with PBS containing 1%
BSA and the bound vWF-Alexa measured by flow cytometry.
Fluorescence Resonance Energy Transfer (FRET)—To assess the
proximity of PDI and GP1ba on the platelet surface, the efficiency of
FRET between PE-labeled PDI and Cy5-labeled GP1ba was measured
by flow cytometry as described previously (41–43). Platelets (2 3 107 in
PDI and GP1ba on the Platelet Plasma Membrane 9759
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100 ml of PBS containing 1% BSA) were incubated with rabbit anti-PDI
polyclonal antibodies (20 mg/ml) and/or the anti-GPIba monoclonal an-
tibody AK2 (20 mg/ml) for 20 min and washed once with PBS containing
1% BSA. The primary antibodies were labeled by incubating for 20 min
in the dark with PE-conjugated donkey anti-rabbit IgG (Becton Dick-
inson, San Jose, CA) or Cy5-conjugated donkey anti-mouse IgG (Jack-
son Immunoresearch, West Grove, PA). The samples were diluted 4-fold
with BSA-free Tyrodes and kept in the dark until analysis. The FRET
efficiency was expressed as the percentage of the emission energy from
donor (PE) taken up by acceptor (Cy5). This method can detect prox-
imity in the 2–10 nm range (41–43).
Effect of Anti-PDI Polyclonal Antibodies on MPB Labeling of
GP1ba—Resting platelets (1 ml of ;7 3 108 per ml for SSB and
;0.4–2 3 109 per ml for MPB) were incubated with 200 mg/ml of either
preimmune rabbit IgG or rabbit anti-PDI IgG for 30 min at room
temperature. The platelets were activated with thrombin, labeled with
either SSB or MPB, and the GP1b-IX-V immunoprecipitated using AK3
monoclonal antibodies as described above. The labeled glycoproteins
were resolved on 10% SDS-PAGE, transferred to PVDF membrane, and
blotted with streptavidin peroxidase to detect the SSB or MPB label.
Binding of Anti-GP1b-IX Monoclonal Antibodies to Platelets—Rest-
ing platelets (2 3 106 in 100 ml of BSA-free Tyrodes buffer) were
incubated with 200 mg/ml of either preimmune rabbit IgG F(ab)2 frag-
ments or rabbit anti-PDI F(ab)2 fragments for 30 min at room temper-
ature. The F(ab)2 fragments were made using the Pierce F(ab)2 Prepa-
ration Kit (Pierce). The platelets were activated with thrombin as
described above and incubated with 10 mg/ml of the following fluores-
cein isothiocyanate-conjugated monoclonal antibodies: MOPC21 (irrel-
evant control, Becton Dickinson, San Jose, CA), SZ1 (anti-GPIX,
Immunotech, Marseille, France), AN51 (anti-GPIba, Dako Pharmaceu-
ticals, Carpinteria, CA), AK2 (anti-GPIba, Serotec, Oxford, United
Kingdom), HIP1 (anti-GPIba, Becton Dickinson, San Jose, CA), and
SZ2 (anti-GPIba, Immunotech, Marseille, France). The samples were
diluted 4-fold with BSA-free Tyrodes and kept in the dark until
analysis.
RESULTS
Platelet Aggregation Triggered an Increase in Platelet Sur-
face Protein Thiol Groups—The membrane impermeable bioti-
nylated thiol-specific reagent, MPB, was used to label sulfhy-
dryl groups on resting or thrombin-activated platelets allowed
to aggregate or prevented from aggregating with ReoPro and
EDTA (Fig. 1A). Platelets were labeled with MPB, sonicated,
resolved on 12% SDS-PAGE, transferred to PVDF membrane,
and blotted with streptavidin peroxidase.
The amount of platelet surface proteins labeled with MPB
increased markedly upon platelet activation/aggregation. Den-
sitometric analysis of the profiles indicated that 460% more
protein was labeled with MPB on activated/aggregated plate-
lets compared with resting platelets. In contrast, far less pro-
tein was labeled with MPB on activated platelets prevented
from aggregating with ReoPro/EDTA, 60% increased labeling
compared with resting platelets. The same result was observed
if EDTA alone was used to minimize platelet aggregation (not
shown). This result implied that platelet activation and aggre-
gation, not activation alone, triggered reduction of platelet
surface protein disulfides or presentation of previously cryptic
protein thiols. The intensity of labeling of individual proteins
with MPB increased with platelet activation/aggregation. In
addition, activation/aggregation-specific MPB-labeled proteins
were also observed. This feature of activated platelets was
examined in more detail by measuring the changes in total
protein on the resting versus activated platelet surface and that
fraction of protein that presented free sulfhydryl group(s).
Quantitation of Thiol- versus Amine-containing Platelet Sur-
face Proteins—Platelet surfaces were labeled with either MPB
or SSB. SSB reacts with primary amines and, therefore, is a
measure of total surface protein. The ratio of thiol- to amine-
labeled surface protein was used to estimate the relative pro-
portion of total platelet surface protein that presented free
sulfhydryl group(s). MPB or SSB was incubated with resting or
thrombin-activated/aggregated platelets. The labeled platelets
were sonicated, resolved on 10% SDS-PAGE, transferred to
PVDF membrane, and blotted with streptavidin-peroxidase to
detect the SSB or MPB label. The profiles of the labeled pro-
teins are shown in Fig. 1B. The greater prevalence of primary
amines compared with sulfhydryl groups on the platelet sur-
face necessitated labeling of 22 times more platelets with MPB
than with SSB.
The amount of platelet surface proteins labeled with SSB
increased significantly upon platelet activation/aggregation.
FIG. 1. Platelet aggregation triggered an increase in platelet
surface protein thiol groups. A, the membrane impermeable thiol-
specific reagent, MPB, was used to label sulfhydryl groups on resting or
thrombin-activated platelets allowed to aggregate or prevented from
aggregating with ReoPro (20 mg/ml) and EDTA (5 mM). Platelets were
labeled with MPB, sonicated, resolved on 12% SDS-PAGE, transferred
to PVDF membrane, and blotted with streptavidin peroxidase to detect
the MPB label. The results represent labeling of 5 3 106 platelets (5 mg).
The positions of Mr markers are shown at the left. B, comparison of
primary amines and thiols on the surface of resting versus thrombin-
activated platelets. Resting and thrombin-activated/aggregated platelet
surfaces were labeled with either SSB or MPB as indicated, sonicated,
resolved on 10% SDS-PAGE, transferred to PVDF membrane, and
blotted with streptavidin peroxidase to detect the SSB or MPB label.
The results represent labeling of 1 3 106 platelets (1 mg) with SSB and
3 3 107 platelets (30 mg) with MPB. The arrows at right indicate
proteins that were labeled with MPB on the activated/aggregated plate-
let surface but were poorly or not labeled on the resting platelet surface.
The asterisks indicate proteins with apparent Mr values of ;60,000 and
;120,000 which may be PDI and GP1ba, respectively (see below). The
positions of Mr markers are shown on the left. C, densitometric analysis
of the SSB-labeled (top) and MPB-labeled (bottom) platelet surface
proteins shown in B. The extent of labeling with either SSB or MPB was
calculated from the areas under the curves. Platelet activation resulted
in a 130% increase in labeling with SSB and 440% increase in labeling
with MPB.
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Densitometric analysis of the profiles indicated that 130% more
protein was labeled with SSB on activated/aggregated platelets
compared with resting platelets. In contrast, 440% more pro-
tein was labeled with MPB on activated/aggregated platelets
compared with resting platelets (see also Fig. 1A). The ratio of
thiol- to amine-labeled protein on resting versus activated/
aggregated platelets was a measure of the relative increase in
surface protein thiols with respect to total surface protein.
Platelet activation/aggregation resulted in a ;190% increase in
surface protein thiol groups. At least 11 proteins presented free
thiol(s) that were labeled with MPB on the activated/aggre-
gated platelet surface but were poorly or not labeled on the
resting platelet surface.
The finding that platelet activation/aggregation resulted in
significantly more labeling of certain platelet surface proteins
with MPB, implied that activation influenced the redox state of
the thiol/disulfide groups of these proteins. PDI is a platelet
surface protein (26, 27) whose activity is regulated by the redox
state of its active site dithiols/disulfides (31). Moreover, PDI
has been shown to regulate the redox state of proteins on the
surface of cultured human fibroblasts (28) and lymphocytes
(29). These findings suggested that PDI might similarly regu-
late the redox state of platelet surface proteins. We investi-
gated the consequence of platelet activation/aggregation for the
redox state of platelet surface PDI.
Platelet Activation Resulted in Reduction of Surface-bound
PDI—The specificity of labeling of oxidized versus reduced PDI
with MPB is shown in Fig. 2A. The active site dithiols of PDI
purified from liver (44) or placenta (31) are oxidized. MPB did
not label purified placenta PDI, as expected, but did label PDI
activated by a low concentration of dithiothreitol (5 mM).
The ratio of thiol- to amine-labeled PDI was used to estimate
the relative proportion of total platelet surface PDI that con-
tained active site dithiols (Fig. 2B). MPB or SSB was incubated
with resting or thrombin-activated/aggregated platelets and
the biotin-labeled proteins purified by affinity chromatography
on streptavidin-agarose beads. The labeled proteins were re-
solved on 10% SDS-PAGE, blotted with anti-PDI polyclonal
antibodies, and quantitated using densitometry. Control reac-
tions omitting the label were performed to ensure that no
unlabeled PDI was being nonspecifically carried through the
procedure (not shown).
Platelet PDI had the same apparent mass of ;57 kDa as
placenta PDI on SDS-PAGE (Fig. 2B), and they share the same
amino-terminal sequence (26, 45). Amine-labeled platelet sur-
face PDI increased 170% upon platelet activation/aggregation
(2,430 6 120 to 6,480 6 320 molecules of PDI per platelet). In
contrast, thiol-labeled PDI increased 750% upon platelet acti-
vation/aggregation (620 6 50 to 5,250 6 240 molecules of PDI
per platelet). Therefore, 26% of the total PDI on resting plate-
lets was in a reduced conformation compared with 81% on
activated/aggregated platelets (Table I). It should be noted that
PDI contains two active site dithiols/disulfides and that this
technique does not distinguish between reduction of one or both
of these disulfides. Therefore, the reduced PDI measured on the
platelet surface is the sum of PDI molecules containing either
one or two active site dithiols.
We hypothesized that the active site disulfides of platelet
surface PDI might be reduced by low Mr thiol compounds
secreted by activated platelets. To test this theory, whole plate-
let and secreted low Mr thiol compounds were measured.
Characterization of Platelet Low Mr Thiol Compounds—
Platelets contain low Mr thiol compounds, in particular GSH
and cysteinylglycine (CysGly) (for example, see Ref. 46). We
compared the low Mr thiol content of thrombin-activated/ag-
gregated platelets and activated platelet releasate from two
healthy individuals. The releasate from 1.5 3 109 thrombin-
activated platelets/ml contained ,0.2 mM low Mr thiol com-
pounds (Fig. 3A). The average concentrations of cysteine, cys-
teinylglycine, and GSH in normal plasma are 9, 3, and 5 mM,
respectively (47). This result indicates that platelets are not a
significant source of plasma low Mr thiols and implied that
platelet surface PDI was not reduced by secreted low Mr thiol
compounds. These observations suggested that activation/ag-
gregation-dependent reduction of platelet surface PDI was me-
FIG. 2. Platelet activation/aggregation resulted in an increase
in both total and reduced platelet surface PDI. A, labeling of PDI
with MPB. Purified placenta PDI (oxidized PDI) or placenta PDI incu-
bated with 5 mM dithiothreitol (reduced PDI) was labeled with MPB,
100 ng of the PDI resolved on 10% SDS-PAGE, transferred to PVDF
membrane, and blotted with streptavidin peroxidase to detect the MPB
label. Placenta PDI (500 ng) blotted with anti-PDI polyclonal antibodies
is shown in lane 1 and migrated at the expected Mr of 57,000. Oxidized
PDI was not labeled with MPB (lane 2), whereas PDI activated with
dithiothreitol incorporated MPB (lane 3). The positions of Mr markers
are shown at the left. B, resting platelets and thrombin-activated/
aggregated platelets were labeled with either SSB or MPB as indicated,
sonicated, and incubated with streptavidin-agarose beads to collect the
biotin-labeled proteins. The labeled proteins were resolved on 10%
SDS-PAGE, transferred to PVDF membrane, and blotted with anti-PDI
polyclonal antibodies. The results represent labeling of 1.6 3 108 plate-
lets (160 mg) with SSB (lanes 3 and 4) and 6.8 3 108 platelets (680 mg)
with MPB (lanes 5 and 6). Control reactions omitting the SSB and MPB
labeling were performed to confirm that no unlabeled platelet PDI was
being nonspecifically carried through the procedure (data not shown).
Controls are purified placenta PDI (100 ng, lane 1) and sonicated whole
platelets (8.3 3 106 platelets, 8 mg, lane 2). The positions of Mr markers
are shown at left.
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diated by protein-catalyzed events.
To further test this hypothesis, the susceptibility of the ac-
tive site disulfides of platelet surface PDI to reduction by di-
thiothreitol was examined. Incubation of resting platelets with
50 mM dithiothreitol for 30 min did not result in any further
reduction of platelet surface PDI (Fig. 3B). In contrast, incuba-
tion of purified PDI with 5 mM dithiothreitol for 30 min was
sufficient to reduce the active site disulfides (Fig. 2A). This
result implied that the redox state of platelet surface PDI was
refractory to extracellular reducing agents.
The results shown in Figs. 1–3 demonstrated that the active
site dithiols/disulfides of PDI were in the dithiol state on the
activated/aggregated platelet surface. At least 11 proteins con-
tained free thiol(s) and were labeled with MPB on the activat-
ed/aggregated platelet surface but were poorly or not labeled on
the resting platelet surface (see Fig. 1B). These proteins were
potential substrates for PDI. One of these proteins had a Mr of
;120, which is the approximate Mr of the platelet receptor for
von Willebrand factor (vWF), GP1ba.
Labeling of Thiol(s) in GP1ba on the Activated Platelet Sur-
face—Resting platelets and thrombin-activated/aggregated
platelets were labeled with either SSB or MPB and the GP1ba
or aIIbb3 immunoprecipitated using either AK3 or AP2 mono-
clonal antibodies, respectively. The labeled glycoproteins were
resolved on 10% SDS-PAGE, transferred to PVDF membrane,
and blotted with streptavidin peroxidase to detect the SSB or
MPB label (Fig. 4). Immunoprecipitation of GP1ba resulted in
co-immunoprecipitation of the GP1bb and GPIX components of
the GP1b-IXzGP-V complex.
GP1ba, GP1bb, and GP-IX were labeled with SSB on resting
and activated platelets. GP1ba was labeled with MPB on acti-
vated platelets, but was not labeled on resting platelets (Fig.
4A). Neither GP1bb nor GP-IX were labeled by MPB on resting
or activated platelets. aIIbb3 is not known to contain unpaired
cysteines, therefore it was an appropriate control for MPB
labeling. Accordingly, aIIbb3 was labeled with SSB but not
with MPB on resting and activated platelets (Fig. 4B).
The results shown in Figs. 1–4 suggested that PDI and
GP1ba may have been physically and/or functionally associ-
ated on the platelet surface. This hypothesis was tested by
measuring the effect of anti-PDI antibodies on binding of vWF
to platelet GP1ba.
Inhibition of Binding of vWF to GP1ba on the Platelet Sur-
face by Anti-PDI Polyclonal Antibodies—In initial experiments
we observed that incubation of platelets with anti-PDI antibod-
ies at concentrations .200 mg/ml resulted in platelet activation
measured by presentation of P-selectin (48). Platelet activation
by 300 mg/ml anti-PDI antibody was blocked completely by the
murine anti-FcgRIIA antibody, IV.3, at concentrations of either
50 or 20 mg/ml. This result indicated that a small fraction of
aggregated IgG in the anti-PDI antibody preparation was bind-
ing to the platelet FcgRIIA receptor and triggering activation.
Washed platelets were incubated with 20 mg/ml IV.3 and 0 to
200 mg/ml control or anti-PDI IgG and the binding of Alexa-
labeled vWF was measured by flow cytometry (Fig. 5). The
anti-PDI IgG reduced binding of vWF to platelets. The effects
were on the apparent dissociation constant for vWF binding
with no discernible effect on the apparent stoichiometry. The
apparent dissociation constant and maximal binding of vWF
was 1.0 6 0.2 mg/ml and 98 6 6% in the presence of control IgG,
and 1.5 6 0.2 mg/ml and 97 6 5% in the presence of 50 mg/ml
anti-PDI IgG. This corresponded to molar dissociation con-
stants of 0.5 6 0.1 and 0.8 6 0.1 nM, respectively, assuming a
weight average Mr for vWF of 2 3 10
6. This affinity is in good
agreement with other estimates of vWF binding (Ref. 49 and
references therein).
These findings supported an association between PDI and
TABLE I
Quantitation of amine- and thiol-labeled platelet surface PDI on
resting and thrombin-activated/aggregated platelets
Molecules of surface PDI per
platelet % PDI
reducedAmine-labeled
PDIa
Thiol-labeled
PDIb
Resting platelets 2,430 6 120c 620 6 50 26
Activated/aggregated platelets 6,480 6 320 5,250 6 240 81
% Increase upon activation 170 750
a Total platelet surface PDI was estimated by labeling platelets with
the membrane-impermeable amine-reactive reagent, SSB.
b Reduced platelet surface PDI was estimated by labeling platelets
with the membrane-impermeable thiol-reactive reagent, MPB.
c The data is presented as the mean 6 range from platelets from two
healthy subjects.
FIG. 3. Platelet surface PDI is refractive to reduction by low
Mr thiols. A, HPLC profiles of platelet low Mr thiol compounds. Platelet
low Mr thiol compounds were derivatized with 7-benzo-2-oxa-1,3-dia-
zole-4-sulfonic acid and separated by reverse-phase HPLC (38). The left
hand trace show the standards, CysGly and GSH, followed by throm-
bin-activated/aggregated platelet sonicate, the same platelet sonicate
spiked with either 2 mM CysGly or GSH to confirm the identity of the
platelet thiols, and finally the releasate from the activated/aggregated
platelets. The chromatograms represent thiols from 3 3 106 thrombin-
activated/aggregated platelets (3 mg), or the releasate from the same
platelets (0.42 mg). The starting sample contained 1.5 3 109 thrombin-
activated/aggregated platelets/ml (1, 500 mg), or the releasate from the
same platelets (210 mg). The HPLC procedure will detect a lower limit
of ;0.2 mM GSH or CysGly in the starting sample. This pattern was
repeated on three separate occasions. B, platelet surface PDI was not
reduced by dithiothreitol. Resting platelets (lane 2), resting platelets
incubated with 50 mM dithiothreitol for 30 min at room temperature
(lane 3), and thrombin-activated/aggregated platelets (lane 4) were
labeled with MPB, sonicated, and incubated with streptavidin-agarose
beads to collect the biotin-labeled proteins. The labeled proteins were
resolved on 10% SDS-PAGE, transferred to PVDF membrane, and
blotted with anti-PDI polyclonal antibodies. The results represent la-
beling of 5.2 3 108 platelets (520 mg). The control for the Western blot
is sonicated whole platelets (8.3 3 106 platelets, 8 mg, lane 1). The
positions of Mr markers are shown at left.
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GP1ba on the platelet surface. To examine directly the prox-
imity of these proteins, FRET between PE-labeled PDI and
Cy5-labeled GP1ba on the platelet surface was measured by
flow cytometry (41–43).
Physical Proximity of PDI and GP1ba on the Platelet Plasma
Membrane Measured by FRET—FRET efficiency is the proba-
bility that an excited donor molecule will transfer its energy to
an acceptor molecule in a non-radiative process and can be
determined either on the donor side (quenching) or the acceptor
side (enhancement). In our experiments we monitored the flu-
orescence intensity on the donor side. First, all fluorescence
intensities were corrected for autofluorescence (Fig. 6A, unla-
beled), that is the mean fluorescence intensity of unlabeled
cells was subtracted from the mean fluorescence intensity of
labeled cells. Second, the mean fluorescence intensity of sample
labeled only with the donor secondary antibody was subtracted
from the mean fluorescence intensity of sample labeled with
donor primary and secondary antibodies and acceptor second-
ary antibody (Fig. 6, anti-PDI/PE, AK2-PE). This value was
Fdonor,corrected and is corrected for nonspecific binding of the
donor PE-conjugated secondary antibody, which was negligi-
ble. Third, the mean fluorescence intensity of sample labeled
only with the donor secondary antibody and the sample labeled
only with the acceptor primary and secondary antibodies was
subtracted from the mean fluorescence intensity of sample
labeled with both donor and acceptor primary and secondary
antibodies (Fig. 6, anti-PDI/PE, AK2/Cy5-PE-AK2/Cy5). This
value was FFRET,corrected and is corrected for the spectral contri-
bution of acceptor Cy5 in the donor PE detection channel, which
was negligible. FRET efficiency was calculated from the rela-
tionship; FRET efficiency 5 1 2 (FFRET,corrected/Fdonor,corrected).
A FRET efficiency of 14.8 6 4.9% (1 S.D.) was calculated
from three experiments. A 14.8% FRET efficiency means that
on average the PE fluorescence intensity of the FRET sample
(labeled with both donor and acceptor molecules) was 14.8%
less than that of the donor sample (labeled with donor molecule
only). A FRET efficiency above 5% is considered significant
(41–43), therefore, our value of 14.8 6 4.9% should be consid-
FIG. 4. Labeling of GP1ba with MPB on the activated platelet
surface. Resting platelets and thrombin-activated/aggregated platelets
were labeled with either SSB or MPB as indicated, sonicated, and the
GP1ba or aIIbb3 immunoprecipitated using either AK3 or AP2 mono-
clonal antibodies, respectively. The labeled glycoproteins were resolved
on 10% SDS-PAGE, transferred to PVDF membrane, and blotted with
streptavidin peroxidase to detect the SSB or MPB label. The results of
labeling of GP1ba are shown in A, while the results of aIIbb3 labeling
are shown in B. The figure represents labeling of 4 3 108 platelets (400
mg). GP1ba, GP1bb, and GP-IX were labeled with SSB on resting and
activated platelets. Platelet activation resulted in a 180% increase in
labeling of GP1ba with SSB. GP1ba was labeled with MPB on activated
platelets, but was not labeled on resting platelets. Neither GP1bb nor
GP-IX were labeled by MPB on resting or activated platelets. aIIbb3
was labeled with SSB but not with MPB on resting and activated
platelets.
FIG. 5. Inhibition of binding of vWF to GP1ba on the platelet
surface by anti-PDI polyclonal antibodies. Washed platelets were
incubated with 20 mg/ml of the anti-platelet FcgRIIA receptor mono-
clonal antibody, IV.3, for 10 min at room temperature and then with 0
to 200 mg/ml of either preimmune rabbit IgG or anti-PDI IgG for a
further 30 min at room temperature. The blocked platelets were incu-
bated with 0.1–10 mg/ml vWF-Alexa and 1 mg/ml ristocetin for 10 min
at room temperature and the bound vWF-Alexa measured by flow
cytometry. The effect of increasing control IgG ( l ) or anti-PDI IgG (E)
on binding of 5 mg/ml vWF-Alexa to platelets is shown in A. The effect
of 50 mg/ml of either control IgG or anti-PDI IgG on the binding of
0.1–10 mg/ml of vWF-Alexa to platelets is shown in B. The lines in B
represent the best fit of the data to the rectangular hyperbolic binding
equation by nonlinear least squares regression. The apparent dissoci-
ation constant and maximal binding of vWF was 1.0 6 0.2 mg/ml and
98 6 6% in the presence of control IgG (—) and 1.5 6 0.2 mg/ml and 97 6
5% in the presence of 50 mg/ml anti-PDI IgG (zzz). In another experiment
the apparent dissociation constant and maximal binding of vWF was
0.9 6 0.4 mg/ml and 83 6 6% in the presence of control IgG and 1.5 6
0.4 mg/ml and 84 6 10% in the presence of 50 mg/ml anti-PDI IgG (data
not shown).
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ered as significant. There was no FRET between PE-labeled
preimmune IgG and Cy5-labeled GP1ba.
It is unlikely that the FRET between PE-labeled PDI and
Cy5-labeled GP1ba occurred by chance. The surface area of a
platelet is 22 mm2 and there are 25,000 molecules of GP1ba
on the platelet surface (49). Therefore, one molecule of GP1ba
will be found in an area of 890 nm2. Assuming an even
lattice-like arrangement, the receptors will be 30 nm apart.
This is well in excess of the upper limit of the Fo¨rster energy
transfer (8–10 nm).
The results shown in Fig. 4 implied that GP1ba underwent a
conformational change upon platelet activation resulting in the
exposure of a free thiol(s). To test whether PDI might be in-
volved in this conformational change, resting platelets were
incubated with anti-PDI antibodies, activated with thrombin,
and labeled with either SSB or MPB or incubated with anti-
GP1b-IX monoclonal antibodies.
Enhancement of Labeling of GP1ba on the Activated Platelet
Surface by Anti-PDI Polyclonal Antibodies—Resting platelets
were incubated with 200 mg/ml of either preimmune rabbit IgG
or rabbit anti-PDI IgG for 30 min, activated with thrombin,
labeled with either SSB or MPB and the GP1b-IXzGP-V immu-
noprecipitated using AK3 monoclonal antibodies. The labeled
glycoproteins were resolved on 10% SDS-PAGE, transferred to
PVDF membrane, and blotted with streptavidin peroxidase to
detect the SSB or MPB label (Fig. 7). The presence of anti-PDI
polyclonal antibodies resulted in a 80% increase in labeling of
GP1ba with SSB and a 130% increase in labeling with MPB.
Incubation of resting platelets (1 3 109 platelets/ml) with
dithiothreitol-activated PDI (0.5 mM) for 10 min, or 200 mg/ml
rabbit anti-PDI IgG for 30 min, at 37 °C did not cause exposure
of the free thiol in GP1ba (not shown). These findings sug-
gested that the conformational change in GP1ba upon platelet
activation was the result of specific events on the activated
platelet surface.
Enhancement of Binding of Anti-GP1ba Monoclonal Anti-
bodies to the Activated Platelet Surface by Anti-PDI Polyclonal
Fab Fragments—Resting platelets were incubated with 200
mg/ml of either preimmune rabbit IgG F(ab)2 fragments or
rabbit anti-PDI F(ab)2 fragments for 30 min, activated with
thrombin, incubated with 10 mg/ml fluorescein isothiocyanate-
conjugated anti-GP1b-IX monoclonal antibodies and the bound
antibody measured by flow cytometry. The GP1b-IXzGP-V com-
plex is in close proximity to the FcgRIIA receptor on the plate-
let surface (48). To eliminate potential complications of anti-
PDI polyclonal antibody binding to the FcgRIIA platelet
receptor, F(ab)2 fragments of the anti-PDI antibodies were
made and used. The binding of one anti-GP-IX monoclonal
antibody and four anti-GP1ba monoclonal antibodies was
measured. SZ1 binds to GPIX in complex with GP1ba. AN51
binds to the N-terminal flank of GP1ba (residues 1–35), while
AK2 binds to the first leucine-rich repeat, HIP1 to the second
leucine-rich repeat, and SZ2 to the anionic sulfated tyrosine
sequence (residues 269–282) (50).
The anti-PDI F(ab)2 fragments did not effect binding of the
irrelevant control antibody, MOPC21. The binding of SZ1,
AN51, AK2, and HIP1 to activated platelets significantly in-
creased upon incubation with anti-PDI F(ab)2 fragments, while
the binding of SZ2 decreased (Fig. 8A). Quantitation of the
effects of anti-PDI polyclonal F(ab)2 fragments on the binding
of the anti-GP1b-IX monoclonal antibodies is shown in Fig. 8B.
The anti-PDI F(ab)2 fragments did not effect binding of any of
the antibodies to resting platelets (not shown).
DISCUSSION
Platelet activation/aggregation resulted in 440% increase in
exofacial protein thiol groups. This increase was dependent on
platelet aggregation, as negligible increase in surface protein
thiol groups was observed if activated platelets were prevented
from aggregating. The increase in surface thiols was due to
expression of new thiol-containing proteins on the platelet sur-
face, generation of thiols by reduction of disulfide bonds in
existing proteins, or presentation of previously cryptic protein
thiols. At least 11 proteins presented free thiol(s) that were
FIG. 6. Physical proximity of PDI and GP1ba on the platelet
plasma membrane measured by FRET. To assess the proximity of
PDI and GP1ba on the platelet surface, the efficiency of FRET between
PE-labeled PDI and Cy5-labeled GP1ba was measured by flow cytom-
etry. The contribution of autofluorescence was determined using unla-
beled cells (a). The binding of the PE-conjugated secondary antibody in
the absence of primary donor antibody is shown in b, while the overlap
of acceptor Cy5 in the donor PE channel is shown in c. FRET between
PE-labeled PDI and Cy5-labeled GP1ba is shown in d. A FRET effi-
ciency of 14.8 6 4.9% (1 S.D.) was calculated from three experiments.
FIG. 7. Enhancement of labeling of GP1ba on the activated
platelet surface by anti-PDI polyclonal antibodies. Resting plate-
lets were incubated with 200 mg/ml of either preimmune rabbit IgG or
rabbit anti-PDI IgG for 30 min, activated with thrombin, labeled with
either SSB or MPB, and the GP1b-IXzGP-V immunoprecipitated using
AK3 monoclonal antibodies. The labeled glycoproteins were resolved on
10% SDS-PAGE, transferred to PVDF membrane, and blotted with
streptavidin peroxidase to detect the SSB or MPB label. The figure
represents labeling of 4 3 108 platelets (0.4 mg). The presence of
anti-PDI polyclonal antibodies resulted in a 80% increase in labeling of
GP1ba with SSB and a 130% increase in labeling with MPB. The
experiment was performed on two separate occasions with the same
qualitative result.
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labeled on the activated/aggregated platelet surface but were
poorly or not labeled on the resting platelet surface. One of
these proteins was PDI.
The ability of PDI to catalyze disulfide interchange in pro-
teins resides in two very reactive surface exposed dithiols/
disulfides which share the common sequence WCGPCK and
have a redox potential of 2110 mV (8–10). Secreted PDI con-
trols the redox state of existing exofacial protein thiols or
reactive disulfide bonds on the surface of human fibroblasts
(28) and lymphocytes (29). The redox status of PDI on resting
and thrombin-activated/aggregated platelets was investigated
by labeling platelets with a thiol- or amine-reactive membrane
impermeable probe.
There were ;2,400 molecules of amine-labeled PDI on the
resting platelet surface versus ;6,500 molecules on the acti-
vated/aggregated platelet surface, an increase of 170%. This
result implied that platelet activation/aggregation resulted in
recruitment of PDI to the platelet surface and/or that a fraction
of the PDI on the resting platelet surface was refractive to
labeling with SSB. Chen et al. (26) reported no clear difference
in the amount of PDI on resting versus activated platelets by
immunogold labeling and electron microscopy, which suggested
that the 170% increase we observed was perhaps due to label-
ing differences between resting and thrombin-activated/aggre-
gated platelets. There is evidence that resting platelets contain
a surface connected compartment, perhaps located in the platelet
surface-connected canalicular system, which can be freely en-
tered by some compounds but not others (51). It may be that the
structure of SSB confers limited access to a pool of PDI on the
resting platelet surface that becomes accessible following throm-
bin activation, which could account for the observed increase in
total PDI on the surface of activated/aggregated platelets.
PDI containing free sulfhydryl groups increased 750% upon
platelet activation/aggregation, and by comparison with amine-
labeled PDI, 81% of the PDI on activated platelets was in a
reduced conformation compared with 26% on resting platelets.
This result indicated that platelet activation/aggregation trig-
gered reduction of the active site disulfides of surface PDI.
Although every effort was made to minimize activation/aggre-
gation of the resting platelets, activation/aggregation of a frac-
tion of the platelets during the washing procedure was almost
unavoidable. The small amount of reduced PDI on the surface
of resting platelets may have represented the fraction of the
total platelets that is activated/aggregated. Therefore, the dif-
ference in amount of reduced PDI on the surface of resting
versus activated/aggregated platelets may have in fact been
greater then we have reported.
No detectable low Mr thiol compounds were secreted upon
platelet activation/aggregation and PDI on the surface of rest-
ing platelets was refractory to reduction by 50 mM dithiothre-
itol. These observations suggested that reduction of platelet
surface PDI was triggered by a secreted or plasma membrane
protein or proteins. It was possible that platelet surface PDI
was intrinsically reduced but that the active site dithiols were
masked by a protein at the platelet surface that was displaced
upon platelet activation/aggregation. However, the activated/
aggregated platelet surface contained 440% more protein thiol
groups other than those of PDI, which implied a more general
reduction event. The report that existing lymphocyte surface
thiols are involved in the generation of additional surface thiols
(29) supports the notion that the active site disulfides of PDI
may have been reduced by an existing platelet surface protein
whose activity was controlled by platelet activation/aggrega-
tion. One possibility is the plasma membrane NADH-oxi-
doreductase system (52) which has been implicated in reduc-
tion of extracellular protein disulfide bonds.
Another protein labeled with MPB on the activated/aggre-
gated platelet surface but not labeled on the resting platelet
surface was GP1ba. GP1ba is part of the GPIb-IXzGP-V com-
plex which mediates adhesion of platelets to vessel wall von
Willebrand factor at high wall shear (53). The thiol labeled in
GP1ba on the activated platelet surface was perhaps the un-
paired cysteine at position 65 in the second leucine-rich repeat
near the N terminus (54). This result indicated that Cys65, or
another cysteine, was not exposed on the resting platelet sur-
face and implied that platelet activation was associated with a
conformational change in GP1ba which exposed Cys65. It is
noteworthy that substitution of Cys65 for Arg in the N-terminal
region of GP1ba impairs binding of vWF to GP1ba (55). It
should be noted, however, that there may have been other free
FIG. 8. Enhancement of binding of anti-GP1ba monoclonal an-
tibodies to the activated platelet surface by anti-PDI polyclonal
F(ab)2 fragments. A, resting platelets were incubated with 200 mg/ml
of either preimmune rabbit IgG F(ab)2 fragments (filled histograms) or
rabbit anti-PDI F(ab)2 fragments (lined histograms) for 30 min, acti-
vated with thrombin, incubated with 10 mg/ml fluorescein isothiocya-
nate-conjugated anti-GP1b-IX monoclonal antibodies and the bound
antibodies measured by flow cytometry. MOPC21 (part i) is an irrele-
vant control antibody, SZ1 (part ii) binds to GPIX in complex with
GP1ba, while AN51 (part iii), AK2 (part iv), HIP1 (part v), and SZ2
(part vi) bind to epitopes in GP1ba (see text for antibody epitopes). B,
quantitation of the effects of anti-PDI polyclonal F(ab)2 fragments on
the binding of the anti-GP1b-IX monoclonal antibodies shown in A.
Monoclonal antibody binding in the presence of control IgG F(ab)2
fragments was gated at 50%, and the binding in the presence of anti-
PDI F(ab)2 fragments was measured. The experiment was performed on
three separate occasions with the same qualitative result.
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thiols in GP1ba or other components of the GPIb-IXzGP-V
complex that were inaccessible or refractive to labeling by MPB
on the platelet surface.
PDI and GP1ba were in close proximity on the activated
platelet surface. Anti-PDI antibodies increased the dissociation
constant for binding of vWF to platelets by ;50% and PDI and
GP1ba were sufficiently close on the platelet surface to allow
FRET between chromophores attached to PDI and GP1ba.
There are approximately 6,500 molecules of PDI (Table I) and
25,000 molecules of GP1ba (49) on the activated platelet sur-
face, therefore the PDI:GP1ba molar ratio was ;1:4. There are
two molecules of GP1ba, GP1bb, and GP-IX and one molecule
of GP-V in a GP1b-IXzGP-V complex on the platelet surface
(53). This translates to an average of one molecule of PDI for
every two (GP1b-IX)2zGP-V complexes.
Incubation of resting platelets with anti-PDI antibodies fol-
lowed by activation with thrombin enhanced labeling and bind-
ing of three monoclonal antibodies to the N-terminal region
(residues 1–74) of GP1ba on the activated platelet surface. In
contrast, binding of a monoclonal antibody to the anionic sul-
fated tyrosine sequence (residues 269–282) was inhibited by
anti-PDI antibodies. The enhanced labeling and antibody bind-
ing to GP1ba in the presence of anti-PDI antibodies may have
been due to simple displacement of PDI from GP1ba by the
anti-PDI antibodies, however, it was possible that the anti-PDI
antibodies were perturbing a PDI-catalyzed conformational
change in GP1ba. The observation that anti-PDI antibodies
caused enhanced binding of three monoclonal antibodies but
decreased binding of another to GP1ba supported a PDI-facil-
itated conformational change. The nature of this putative con-
formational change is unknown, but it is noteworthy that PDI
can catalyze net formation, net rearrangement, or net reduc-
tion of protein disulfide bonds depending on the nature of the
protein substrate, the redox conditions, and the presence of
other thiols and disulfides (10).
These studies point to a control mechanism that is analogous
to activation of platelet aIIbb3 (56). On the resting platelet
surface aIIbb3 is in a conformation that does not bind its
ligands. Platelet activation triggers a conformational change in
aIIbb3 which enables ligand binding (57). Similarly, platelet
activation/aggregation triggered reduction of the active site
disulfides of PDI and a conformational change in GP1ba that
resulted in exposure of a free thiol(s). The fact that PDI and
GP1ba were in close proximity on the activated platelet surface
suggested that PDI may have influenced the conformational
change in GP1ba. An important question is what consequence
the conformational change in GP1ba has for its interaction
with vWF. It is possible that the change causes displacement of
vWF from GP1ba. This might facilitate platelet spreading.
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